<qa>  What is the only way to treat allogeneic CD8 PR3-specific CPatients receive allogeneic CD8 PR3-specific CTLs intravenously IV over 1-2 hours on days 0, 7, 14, 28, and 49 and aldesleukin subcutaneously SC twice daily on days 28-41 and 49-63 in the absence of unacceptable toxicity. 